1 TITLE PAGE

2	
3	Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor
4	Kidneys Predict 12-Month Posttransplant Outcome
5	
6	Authors: Philip D Charles ^{1,2†} , Sarah Fawaz ^{3,4*} , Rebecca H Vaughan ^{3,4*} , Simon Davis ² , Priyanka
7	Joshi ³ , Iolanda Vendrell ² , Ka Ho Tam ⁵ , Roman Fischer ² , Benedikt M Kessler ² , Edward J
8	Sharples ⁶ , Alberto Santos ^{1,7,8} , Rutger J Ploeg ^{3,4} , Maria Kaisar ^{3,4†}
9	
10	Affiliations:
11	¹ Big Data Institute, Nuffield Department of Medicine, University of Oxford; Oxford, United
12	Kingdom.
13	² Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine,
14	University of Oxford; Oxford, United Kingdom.
15	³ Research and Development, NHS Blood and Transplant; Bristol & Oxford, United Kingdom.
16	⁴ Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University
17	of Oxford; Oxford, United Kingdom.
18	⁵ Engineering Department, University of Oxford; United Kingdom.
19	⁶ University Hospital Oxford; Oxford, United Kingdom.

- ²⁰ ⁷Center for Health Data Science, University of Copenhagen; Copenhagen, Denmark.
- ²¹ ⁸Novo Nordisk Foundation Center for Protein Research, University of Copenhagen;
- 22 Copenhagen, Denmark.
- 23 *These authors contributed equally.
- 24
- 25 †Corresponding authors. Email: <u>philip.charles@ndm.ox.ac.uk; maria.kaisar@nds.ox.ac.uk</u>
- 26
- 27 Keywords:
- 28 Kidney transplantation, Machine Learning, Data Independent Acquisition, Proteomics, Donor
- 29 Age, QUOD
- 30
- 31

32 ABSTRACT

33	Background . Organ availability limits kidney transplantation, the best treatment for end-
34	stage kidney disease. Deceased donor acceptance criteria have been relaxed to include older
35	donors with higher risk of inferior posttransplant outcomes. Donor age, although significantly
36	correlates with transplant outcomes, lacks granularity in predicting graft dysfunction. Better
37	characterization of the biological mechanisms associated with deceased donor organ damage and
38	specifically predictive of transplant outcome in recipients is key to developing new assessment
39	criteria for donor kidneys and developing function-preserving interventions.
40	Methods. 185 deceased donor pretransplant biopsies with clinical and demographic
41	donor and recipient metadata were obtained from the Quality in Organ Donation biobank
42	(QUOD), selected on the basis of 12-month paired posttransplant function and deep proteomic
43	profiles acquired by mass spectrometry. Using a 2/3 rd :1/3 rd training:test data split, sampling
44	equally across posttransplant function, we applied machine learning feature selection followed
45	by protein-wise relaxed LASSO regression modeling, assessing the performance of the final set
46	of protein models on the test data. Western blotting validated protein changes, and the biological
47	relevance of the final set of protein models was externally validated by contextualization against
48	a published dataset of human healthy and disease kidney transcriptomes.
49	Results. Our analysis revealed 144 proteins carrying outcome-predictive information, all
50	of which showed donor-age modulated associations with posttransplant function, as opposed to
51	age and protein/gene effects being independent terms. Observed associations with inflammatory,
52	metabolic, protein processing and cell cycle pathways suggest biological targets for possible

53 interventions pretransplant. Contextualization of our results against external spatial

54 transcriptomic data suggest a sub-nephrotic spatial localization of the predictive signal.

55 **Conclusions.** Integrating kidney proteome information with clinical metadata enhances 56 the resolution of donor kidney quality stratification, and the highlighted biological mechanisms 57 open new research directions in developing predictive models and novel interventions during 58 donor management or preservation to improve kidney transplant outcome.

59

60 SIGNIFICANCE STATEMENT

61 Currently, organ quality assessment pretransplant relies on key factors such as donor age or clinical information, these lack granularity in depicting graft susceptibility and capacity to 62 function posttransplant. A high-resolution proteomic profiling of 185 pretransplant biopsies of 63 64 kidneys with known posttransplant function and complete metadata was performed. Integration 65 of donor kidney proteomes with 56 clinical metadata variables using regularized regression modelling resulted in enhancing the resolution of donor kidney quality stratification. Immuno-66 metabolic and catabolic processes contributed to donor kidney susceptibility and worse 67 68 transplant outcomes in an age modulated pattern, validated by western blotting. Comparison of 69 kidney proteomes with a recent transcriptomics dataset of healthy and diseased kidneys provide an additional special single cell resolution to the findings of this study. 70

71

72

73 INTRODUCTION

Kidney transplantation is the optimal treatment for end-stage kidney disease. Compared to dialysis, transplantation increases life-expectancy, improves quality of life and is costeffective. Limited availability of suitable donor kidneys impedes treatment of chronic kidney disease, and often prolongs dialysis, increasing morbidity and mortality. Deceased donor organ shortages, living donation decline in some countries and emerging ageing populations drive increased utilization of older deceased donor kidneys, now comprising more than half of offered organs^{1,2}.

Ageing associates with time-dependent decline of organ function, evidenced in kidneys 81 by histologic lesions, such as tubular atrophy, interstitial fibrosis, glomerulosclerosis, and 82 83 arteriosclerosis. Older kidneys demonstrate fewer functioning glomeruli, less renal mass, podocyte dysfunction, and impaired cellular repair³. Glomerular diseases are more common and 84 associated with worse outcomes in older patients⁴. Age accelerates the transition from Acute 85 Kidney Injury (AKI) to chronic injury⁵ and is an independent risk factor of graft dysfunction and 86 loss for deceased donor kidneys⁶; furthermore, older donors are more likely to suffer from 87 additional risk factors such as diabetes, hypertension or cardiovascular disease. 88

Donor age is incorporated in clinical scoring algorithms to inform kidney allocation
 decisions^{7,8}, but is insufficient to consistently predict transplant outcomes. Current front-line
 models incorporating further clinical factors such as terminal serum creatinine, history of
 hypertension and diabetes^{8,9} show consistent performance across demographics but lack granular
 predictive accuracy¹⁰.

Molecular analyses of biopsies plausibly offer higher resolution assessment of organ
 state; but require 'big picture' understanding of mechanisms associated specifically with poor

outcome, rather than immediate (but potentially recoverable) acute injury. Deceased donors are
frequently assessed as having sustained damage (i.e. AKI) based on serum creatinine levels¹¹,
however this metric poorly associates with longer term outcomes¹¹⁻¹⁴.

Mass spectrometry (MS) proteomic studies can provide such a 'big picture', but have
heretofore lacked cohort capacity to represent demographic diversity¹⁵. Advances in highthroughput techniques¹⁶ now allow sensitivity and depth without sacrificing throughput capacity.
Developments in machine learning and nonlinear regression analyses furthermore offer tools to
extract maximal knowledge from limited size experimental cohorts, with applications in disease
staging, disease recurrence prediction, treatment response monitoring, and biomarker
identification^{17,18}.

Integration of deep proteomic profiles with heterogenous clinical and demographic
 factors using modern statistical tools can empower the next steps toward precision medicine¹⁹.
 Here, we benefit from the granularity provided by our MS-based proteomic profiling to report
 age- and immunometabolism-related proteomic signatures in pre-implantation kidney biopsies
 associated with transplant outcomes.

111

112 METHODS

113 Study Design

Deceased donor pre-transplantation kidney biopsies (n=186; 1 sample excluded during data processing) were obtained from the Quality in Organ Donor (QUOD) biobank, a national multi-center UK wide bioresource of deceased donor clinical samples acquired during donor management and organ procurement. Biopsies were obtained from Donation after Brain Death

(DBD) donors and Donation after Circulatory Death (DCD) donors at the back table immediately
after kidney procurement.

120	Selection of biopsies was based on paired 12-month post-transplant outcomes. To
121	minimize the impact of recipient factors, we only included kidneys for which the contralateral
122	kidney was transplanted with similar outcome. Kidneys were selected to cover the outcome
123	continuum i.e. the range of estimated Glomerular Filtration Rate (eGFR) in the recipient at 12
124	months posttransplant (henceforth, 'eGFR12'), from primary non-function to eGFR>80
125	ml/min/1.73 m ² , excluding pediatric donors. Samples were linked to corresponding donor and
126	recipient demographic and clinical metadata, provided by NHS Blood and Transplant National
127	Registry.

128 Study Approval and Ethics statement

129 Informed consent from donor families was obtained prior to sample procurement.

130 Collection of QUOD samples and research ethics approval was provided by QUOD

131 (NW/18/0187).

132 **Protein Extraction from Renal Tissue Specimens**

Deceased donor biopsies were procured, handled and stored according to consistent, predefined collection protocols designed to minimize pre-analytical variability. Donor kidney biopsies were collected ex situ immediately after flush-out and procurement of the kidney in the donor hospital on the back-table. Biopsies were obtained from the upper pole of the donor kidney cortex during back table preparation, using a 23mm needle biopsy gun. The obtained biopsies were divided in two, with one half stored in RNAlater (Thermo Scientific, Illinois, USA), then liquid nitrogen and the other half stored in formalin.

RNAlater biopsy samples were homogenized in RIPA buffer (89900, Thermo Scientific,
Illinois, USA) with protease and phosphatase inhibitor cocktail (1861280, Thermo Scientific,
Illinois, USA) using a bead beater (Biorad, Hertfordshire, UK) at 6500rpm for three cycles of 40
seconds with intermediate cooling on wet ice between cycles. Biopsy protein concentration was
determined using a Pierce Bicinchoninic Acid protein assay kit (23227 Thermo Scientific,
Illinois, USA).

146 In-Solution Trypsin Digestion

50 µg of protein homogenates were prepared. Disulfide bonds were reduced by adding
200 mM of DTT (Sigma) to a final concentration of 5 mM for 60 mins at room temperature. Free
cysteine residues were alkylated by adding 200 mM of iodoacetamide (Sigma) to a final
concentration of 20 mM and incubated for 60 mins at RT in the dark.

The samples were topped up to 200 µl with 6 M urea, 100 mM TrisHCl pH 8.5. 151 152 Methanol/chloroform protein precipitation was used to remove detergents before tryptic 153 digestion. In brief, 600 µl of Methanol and 150 µl of Chloroform were added and mixed. Then 154 450 µl of MilliQ-H2O was added and then centrifuged for 1min at 12,000 g. The upper aqueous layer was carefully removed without disturbing formed protein pellets between layers and 450 µl 155 of Methanol was added and then centrifuged at 12,000 g for 5 min. The supernatant was removed 156 157 and the protein pellets resuspended in 50 µl of 6 M Urea, 100 mM TrisHCl, pH 8.5. Urea concentration was reduced to 1 M by adding 250 µl of MillQ-H2O. Samples were digested at 37 158 °C overnight with Trypsin added at a 1:50 ratio (trypsin:protein). Tryptic peptides were acidified 159 160 and purified using Sep-Pak C18 cartridges (WAT020515, Waters, Wilmslow, UK) and dried by 161 Speed Vac centrifugation. Pellets were resuspended in 80 µl of resuspension buffer A (98 % MilliQ-H2O, 2 % acetonitrile 0.1 % formic acid) for LC-MS/MS analysis. 162

163 Mass Spectrometry Analysis

164 Generation of Fractionated Pool for Spectral Library Reference

165 A highly fractionated spectral library was generated as a standard reference for the subsequent analysis of individual samples. To create this spectral library, a pool sample was 166 prepared by combining 2 μ l of each tryptic digest sample prepared above. Fractionation of the 167 pooled sample was performed using offline high-pH reverse-phase HPLC on an XBridge BEH 168 C18 XP column (3×150 mm, 2.5 µm pore size, Waters no. 186006710) over a 100-minute 169 gradient (Buffer A: water, pH10 with ammonium hydroxide. Buffer B: 90 % acetonitrile, 10 % 170 water, pH10 with ammonium hydroxide) with fractions collected every 2 minutes. The fractions 171 of the pool sample for the spectral library were analyzed by nanoLC-MS/MS using a Dionex 172 173 Ultimate 3000 using a 75 µm x 500 mm (2 µm particle size) C18 EASY-Spray column at 250 nL/min (Thermo Scientific), coupled to an Orbitrap Fusion Lumos mass spectrometer. Peptides 174 were separated using a 60-minute linear gradient from 2-35 % buffer B (Buffer A: 5 % DMSO, 175 176 0.1 % formic acid in water. Buffer B: 5 % DMSO, 0.1 % formic acid in acetonitrile). The 177 samples were analyzed on the mass spectrometer in Data-Dependent Acquisition mode. MS1 scans were acquired in the Orbitrap with an m/z range of 400 - 1500 m/z at a resolution of 178 120,000 and an AGC target of 4 x 10^5 . Precursors between charge states 2+ and 7+ were selected 179 180 for HCD fragmentation using the Advanced Precursor Determination option with an intensity threshold of 2.5 x 10^4 . Selected precursors were isolated using the quadrupole with a 1.6 m/z 181 182 isolation window and fragmented using HCD with a normalized collision energy of 30%. MS2 spectra were acquired in the Orbitrap using a resolution of 30,000, a maximum injection time of 183 54 ms and an AGC target of 5 x 10^4 . 184

185 LC-MS/MS Analysis of Individual Biological Samples

186	The individual samples were analyzed on the same nanoLC-MS/MS system as above. A
187	45-minute linear gradient was used from 2-35 % buffer B with the same buffer composition as
188	above. In contrast to the pool samples, the individual samples were analyzed using the SWATH
189	DIA method ¹⁶ . The sample analysis order was randomized, and analyses of aliquots of the
190	pooled sample used for library generation were scheduled every 20 runs throughout the sequence
191	as a quality control. MS1 scans were acquired in the Orbitrap with an m/z range of $350 - 1650$
192	m/z at a resolution of 120,000, an AGC target of 4 x 105 and a 3 second cycle time. MS2 scans
193	were then acquired in stepped isolation windows with a 1 Th overlap between each window; first
194	from 350-380 m/z up to 930-960 m/z in increments of 30 Th (i.e. 21 scans with midpoints of
195	365, 394 916, 945), followed by a 100 Th window scan of 959-1059 m/z and a 592 Th scan of
196	1058-1650 m/z.

Fragmentation of these windows was performed using a normalized collision energy of 25 %
with a stepped collision energy of 10 %. MS2 spectra were acquired in the Orbitrap using a
resolution of 30,000, a maximum injection time of 54 ms, an AGC target of 5 x 104 and a scan
range of 360-1650 m/z.

201 Western Blot Validation

Samples were compared as 5 Upper Tertile (UT) versus 5 Lower Tertile (LT)within a single age category (younger; total n=20, or older; total n=20) on each gel. Kidney homogenates at 1 μ g/ μ L of protein were denatured at 90 \Box C in Laemmli buffer and separated using 4-12% precast Bis-Tris gels (Thermo Fisher Scientific, Massachusetts, USA) in the case of VTN and APOE western blots and 16% pre-cast Tricine gels (Thermo Fisher Scientific, Massachusetts, USA) in the case of PREB and CST3 western blots, in both cases using MOPS running buffer and followed by transfer onto a PVDF membrane (Thermo Fisher Scientific, Massachusetts,

209	USA). Membranes were then blocked in Intercept (TBS) Blocking Buffer (LiCOR P/N 927-
210	60001) and incubated with primary antibodies overnight at $4 \square C$. Antibodies used were rabbit
211	polyclonal anti-PREB (Thermo Fisher Scientific PA5-53125), mouse polyclonal anti-Vitronectin
212	(R&D, MAB2349), rabbit monoclonal anti-APOE (16H22L18) (Thermo Fisher Scientific,
213	701241), rabbit monoclonal anti-CST3 (D6U3E) (Cell Signaling Technology, 24840) and
214	mouse monoclonal anti- β -actin (Sigma, A5316) for protein normalization. The membranes were
215	then incubated in species appropriate secondary antibodies (RDye® 800CW Goat anti-Mouse
216	IgG Secondary Antibody and IRDye® 680RD Goat Anti-Rabbit IgG Secondary Antibody,
217	LiCOR, USA). Finally, blots were imaged using the LI-COR Odyssey system (LiCOR,
218	Nebraska, USA). Analysis and quantification were performed using LiCOR Image Studio
219	(Version 2.2). Protein expression was normalized against β -actin and the fold change was
220	calculated relative to the per-gel mean value of the Upper Tertile group. For each protein, fold
221	changes relative to UT were combined across all gels within each age category, log2
222	transformed, and the difference between UT and LT calculated by t-testing without assumption
223	of equal variance.

224 Statistical Analyses

225 Proteomic Data Processing

Both the DDA fractionated pools and all SWATH samples and pool data were analyzed simultaneously using DIA-NN v1.7.12 ²⁰. MS/MS spectra from the DDA pools were searched against UniProt Reference *Homo sapiens* database (retrieved 15/10/2020) with default settings, including 1 missed cleavage, oxidation of methionine as a variable modification and carbamidomethylation of cysteine as a fixed modification, to generate a spectral library. This

231	was then cross referenced against the SWATH data to quantify peptides, and thus proteins,
232	within each SWATH sample and pool run. Precursor FDR was set to 1%.
233	Subsequent analysis of the DIA-NN output and integration with the clinical data was
234	performed in R v4.0.2. One sample had extremely low average intensity and more than 15%
235	missing values, so was eliminated from the analysis. Across the remaining 185 samples and
236	pools, proteins with more than 50% missing values were eliminated. Intensity values were
237	transformed by VSN (R package 'vsn' ²¹), and the remaining missing values were imputed by a
238	k-nearest neighbor approach (R package 'impute' ²²).
239	Clinical Variable Preprocessing
240	Clinical variables were subdivided into Donation after Brain Death (DBD)-specific
241	variables, Donation after Cardiac Death (DCD)-specific variables and jointly applicable
242	variables (see annotation, Supplementary Table 1). DBD- and DCD-specific variables were
243	considered for the purposes of assessing correlation with outcome but were not considered for
244	statistical analyses applied to the full dataset.
245	For significance testing of outcome differences between donor and recipient
246	characteristics, and for all modelling, eGFR values for both donor measurements and recipient
247	measurements at 12-month post-transplantation were stratified into tertiles - Lower Tertile (UT;
248	eGFR < 40), Intermediate Tertile (IT; $40 \le eGFR < 60$) and Upper Tertile (UT; $eGFR \ge 60$)
249	based on their distribution. Missing values in the continuous and tertile-stratified forms of the
250	variables were imputed for each sample by finding the 'set of neighbors' by 3-month eGFR, i.e.
251	the 10 samples with the closest recipient eGFR at 3 months posttransplant, then taking the mean
252	eGFR12 (ignoring any missing values) within that set of neighbors.

We curated the non-DBD/DCD specific clinical variables to remove those inappropriate for modelling (single-instance categories, variables which duplicated another variable in different units); the final list is given in Supplementary Table 2. HLA mismatches were modelled as 'Match Grade' with levels None; no mismatches, Favorable; no DR and one or fewer B mismatches, and Non-Favorable; at least one DR or two B mismatches (Supplementary Figure S2 and Supplementary Table ST1).

For curated clinical variables, missing values were imputed for each sample in a similar manner. A set of neighbors was built by finding the 10 samples with the smallest Gower's distance across all variables (multiple data types). We then took a relevant summary statistic of the non-missing values within the set of neighbors for each imputed value. For numeric values, the mean was taken. For categorical values, the most frequent category across the whole dataset was taken, breaking ties by iteratively shrinking the set of neighbors by removing the most distant from the sample to be imputed, until there was a single most frequent category.

266 Outcome Subgroup Comparison

Differences between outcome subgroups within DBD and DCD donor types (separately) were tested using Fisher's exact test for categorical variables and t-tests for numeric variables as appropriate.

Clinical variable association was calculated depending on the type of each variable in pairwise comparisons. Numeric-numeric comparisons were by Pearson's r. Numeric-categorical comparisons were by the square root of the proportion of variance explained (eta) from an ANOVA model where the numeric variable was taken as the response. Categorical-categorical comparisons were by Cramér's V. Hierarchical clustering was performed using the single-linkage method to avoid composition of comparison types.

The proteomic and clinical data were matched in R by sample identifier. Based on an initial scree plot of the variance distribution, unsupervised clustering of the proteomic data was performed by k-means clustering with k=4. The number of initial random centroids and the maximum number of iterations were both set to 10.

280 Training and Test Data Split

We split our data into a training and test sets, sampling equally across stratified eGFR. Of the 185 samples, 2/3 were used for training ('training set', 118 kidneys), and 1/3 were used for testing ('test set', 61 kidneys). Six paired kidneys (3 pairs) were reserved from both sets and used to assess MS and model performance ('QC set', 6 kidneys).

285 Machine Learning Feature Selection

286 Using sample assigned to the training dataset, we modelled the combined dataset of all protein abundance data plus the curated donor clinical variables (Supplementary Table S2) 287 against ranked 12 month posttransplant eGFR, using Prediction Rule Ensemble (PRE) modelling 288 (R package 'pre'²³). We used the 'gpe' function allowing linear fits, decision tree fits and 289 multivariate adaptive regression spline fits (via R package 'earth' ²⁴) to be considered for each 290 ensemble. Decision tree learning was set to be 'random forest'-like, with 500 initial trees 291 generated and boosting disabled to allow parallel processing. Other settings (including tree 292 pruning and the parameters for linear and spline fits) were left as default; tree depth was 293 therefore limited to the default 3 decision levels. Ensemble modelling was performed in an 294 iterative manner. At each stage, modelling was performed on the set of predictors that excluded 295 proteins listed in the final ensemble of all previous models. Clinical variables were never 296 excluded. Modelling was repeated for 2000 iterations and all proteins appearing in any rule 297

ensemble, or with high correlation (Pearson's r>0.65) to any of these candidates, were selected
for further analysis.

300 Regression Modelling

Based on the outcome of feature selection, we used regularized regression (relaxed 301 LASSO, package 'glmnet', using the cv.glmnet function with 20-fold cross validation, selecting 302 as the final model the model that maximized the shrinkage parameter lambda such that it was 303 within 1 standard error of the lambda value that had the smallest cross-validation error, i.e. the 304 'lambda.1se' model) to regress each protein, donor age and protein: age terms against linearized 305 outcome, defined as the proportion of eGFR12 values in the NHS Blood and Transplant National 306 Registry between 2016 and 2021 inclusive (6 years) that were less than the observed eGFR12 307 308 (i.e. a normalization to population distribution quantile). An independent age-only model was also fit against the training dataset using the same parameters. For each protein model and the 309 age-only model we calculated the prediction root-mean-square error (RMSE). Proteins with a 310 311 higher RMSE than the independent donor age model, or whose model did not retain either the protein or protein:age term were discarded. 312

313 Functional Network Analysis

The final list of proteins resulting from regression modelling was queried using the Enrichr platform (R package 'enrichR'²⁵) against the Reactome 2022 database. Annotation term assignments were filtered at 5% FDR. From the set of candidates with at least one assigned term across all three databases, a connection graph was generated (R package 'igraph'²⁶) with nodes representing proteins and edges representing shared annotation terms. Nodes (proteins) were clustered using the walktrap community detection algorithm²⁷ as implemented in igraph. Withincommunity enrichment for annotation terms was calculated by Fisher's exact test.

321 Age-Protein-Outcome Clustering

322	For each protein, eGFR12 was predicted using the corresponding relaxed LASSO model							
323	for donor ages 20,21,2280 and protein quantiles 0,0.01,0.021, resulting in a 61x101 matrix.							
324	Matrix-matrix distances were computed using the Frobenius distance (R package							
325	'StatPerMeCo' ²⁸), and proteins were clustered according to these pairwise distances by							
326	hierarchical clustering.							
327	Spatial Correlation Analysis							
328	Processed, normalized AKI and CKD spatial scRNA-seq expression data generated by							
329	Lake <i>et al.</i> ²⁹ were obtained from CELLxGENE							
330	(https://cellxgene.cziscience.com/collections/bcb61471- 2a44-4d00-a0af-ff085512674c).							
331	Proteins identified by feature selection and LASSO regression filtering were matched to the							
332	expression dataset by the 'Genes' column in the DIA-NN output. AKI:CKD correlation in							
333	matched versus unmatched genes in each characterized spatial location was compared using the							
334	approach described by Fisher ³⁰ (R package 'cocor' ³¹).							
335								
336	RESULTS							
337	Selected Samples were Demographically Balanced Across Outcome Strata							
338	Samples were selected to provide a balanced representation of the UK donor population							
339	(Table 1) and reproduced generally observed trends in terms of the correlation between eGFR12							
340	and clinical variables; we found the strongest associations were donor age (Pearson's r =-0.52),							
341	and recipient age (r =-0.28) (Supplementary Figure S1).							

342	For an interpretable analysis of key clinical factors, we considered our samples by
343	eGFR12 stratum Lower Tertile (LT; eGFR12 < 40), Intermediate Tertile (IT; 40≤eGFR12<60),
344	and Upper Tertile (UT; eGFR12 \geq 60) all units ml/min/1.73 m ² (Figure 1). We investigated
345	associations between clinical variables and stratified eGFR12 subgroups within each donor type,
346	and between donor types within stratified eGFR12 subgroups (Supplementary Table ST1); the
347	only variables with significant difference between outcome groups across donor types were the
348	UK Kidney Donor Risk Index; UKKDRI ⁸ (ANOVA F-test; DBD: p=1.298e-6; DCD: p=3.946e-
349	7), donor age (ANOVA F-test; DBD: p=1.253e-9; DCD: p=1.196e-7), histories of hypertension
350	(ANOVA F-test; DBD: p=0.0020; DCD: p=0.1069). Histories of diabetes (ANOVA F-test;
351	p=0.6188; DCD: p=0.2348) and terminal serum creatinine levels (ANOVA F-test; DBD:
352	p=0.6972; DCD: p=0.6448) were similar across outcome subgroups although the latter was
353	higher in DBD than in DCD in the UT group (t-test; p=0.0443).
354	Integration of Kidney Proteomes with Clinical Metadata by Rule Ensemble and Regression
355	Modelling Identifies Outcome-Associated Proteins
356	Proteomic analysis quantified 2984 protein groups with 50% or less missing values (out
357	of 7790 identified protein groups in total) over 185 samples and 20 interspersed sample pools
358	(Supplementary Figure S2A). Analysis of sample pools showed minimal sample acquisition-
359	related variance (squared mean pairwise Z-corrected Pearson's $r=0.94$). The 3 pairs of kidneys
360	showed high correlation of protein intensity values between donor pairs (Pearson's $r=0.71, 0.92$
361	and 0.91; Supplementary Figure S2B).
362	We initially explored the proteomic data using Principal Component Analysis (PCA) to
363	find underlying linear trands. Complexing a concentrated in the first two gringing loger events
	find underlying linear trends. Sample variance concentrated in the first two principal components

(Figure S3; Figure S4A) which associated with donor type, with a preponderance of DBD
samples towards Cluster 2 and a preponderance of DCD samples towards Cluster 4 (Figure S4B,
upper left panel; p=0.0235), but did not associate strongly with recipient eGFR (p=0.4134),
donor eGFR (p=0.1684), or donor age (p=0.7907) (Figure S4B, upper middle, upper right and
lower left panels). There was a weakly significant association between cluster membership and
donor BMI (p=0.0350) and with donor serum creatinine (p=0.0326) (Figure S4B, lower middle

To assess individual protein relationships with outcome, we adopted a descriptive 372 modelling approach, using a subset of our data ('training set'; 2/3 of data) to find protein models 373 374 which predicted eGFR12 better than donor clinical data alone, then assessing model performance against unseen (i.e. held out) test data ('test set', 1/3 of data). Six of the kidneys analyzed (3 375 pairs) were pairs from the same donor; these were reserved from both training and test data for 376 quality control ('QC set', 6 kidneys). To create our train/test split, we randomly selected equal 377 numbers of samples for the training set within each of the eGFR12 strata described above, to 378 sample equally across outcome range. 379

To identify possible outcome-associated proteins, relevant clinical variables and potential 380 protein-clinical variable interactions, we used iterative Prediction Rule Ensembles²³ (PRE) 381 382 learning on our training set to select features among the set of quantified proteins and donor 383 type-independent donor clinical variables. Briefly, PRE identifies a minimal ensemble of 384 explanatory rule (functions of variables) for a given response (here, ranked eGFR12) allowing for nonlinear associations and variable interactions. To build a catalog (rather than minimal set) 385 of explanatory proteins, we repeated our analysis 2000 times, removing proteins identified in the 386 rule ensemble at each iteration from the dataset for future iterations, retaining clinical variables. 387

This process generated 195 candidate proteins; we further supplemented this list with proteins that had high correlation (Pearson's r>0.65) with any of those candidates; bringing the final list up to 255 candidates.

The only donor clinical variable term to feature consistently in rule ensembles was donor 391 age, appearing in all 2000 ensembles generated. We individually tested each protein candidate 392 for association with outcome, including protein, donor age, and age:protein interaction terms 393 using LASSO regression³² to aim for the simplest explanatory models (i.e. that include only the 394 minimum necessary terms). To ensure models would generalize beyond our data, for the final 395 modelling we linearized the eGFR12 measurement against UK NHS Blood and Transplant 396 397 National Registry data. We discarded candidates whose model discarded both the protein and age:protein terms, or had a higher root-mean-square error (RMSE) of prediction than a model 398 built with donor age alone. 399

After filtering we had identified 144 proteins which associated with outcome (Supplementary Table 2). The mean RMSE of our protein models was 25.76 ml/min/1.73m² in our training data, and fell slightly to 22.25 ml/min/1.73m² in our test data, indicating the models were not over-fit (Supplementary Figure S5).

Functional Analysis of Outcome-Associated Proteins Reveals Immuno-Metabolic Pathway
 Clusters

We performed a network analysis of shared Reactome pathways (Figure 2A). Walktrap clustering revealed 4 major clusters of shared-pathway proteins (Table 2); Immune Regulation & Complement Activation, Metabolism, Protein Metabolism & Modification, and Cell Cycle. To validate our findings, we selected three representative proteins with available antibodies and known biological relevance (Vitronectin (VTN); fibrosis, Apolipoprotein E (APOE); CKD risk,

Cystatin C (CST3); nephron function) and confirmed that all three showed differences between low and high eGFR outcome sample subgroups by western blot (Figure 2B). Furthermore, all three proteins consistently predicted similar outcomes for each pair of kidneys within the triplepair QC set, and correctly separated the two below-median outcome (eGFR12<50) pairs from the above-median outcome (eGFR12>50) pair (Figure S6).

416 Association of Proteins with Posttransplant Outcome is Modulated by Donor Age

For all 144 proteins, the minimal model retained an age:protein interaction term where 417 the predictive effect of protein abundance was modulated by age, independent of the effect of 418 age alone or protein abundance alone (Supplementary Table 2). To visualize these effects, we 419 used each model to predict eGFR12 across increasing donor age and protein quantile. The 420 421 interplay between protein quantile and age could be broadly grouped (by hierarchical clustering) into 3 clusters with protein to eGFR12 associations that showed different patterns across donor 422 423 age (Figure 3), with about a third (31%) of candidates, including CST3, falling into a cluster with 424 a profound effect of age on protein to eGFR12 association at high donor age.

425 Comparison to Spatial scRNA-Seq Data Reveals Localization of Outcome-Associated 426 Signal

As an independent validation of our findings, we sought to contextualize them in the wider context of kidney damage. To do this, we compared the expression levels of our candidate protein set to a recent spatial scRNA-seq dataset comparing AKI and CKD²⁹. This initial comparison revealed that all 144 of our candidates were matched to transcripts reported in this external dataset, and, consistent with our proteomic data. Two of our highlighted candidates associated with outcomes, APOE and CST3, were also highlighted as associated with fibrosis and inflammation damaged tubules in this dataset.

We then investigated how the expression levels of transcripts corresponding to our set of 434 144 proteins changed between AKI and CKD. We reasoned that protein and gene expression 435 data that carries outcome-predictive information must reflect differences in organ injury. 436 Therefore, between different injurious scenarios, we would expect gene expression that is 437 predictive (i.e. discriminatory) to have lower correlation than genes whose expression change 438 439 was linked to general inflammation and stress response. We compared the AKI:CKD expression correlation of our set of candidates versus the expression correlation of all other transcripts in the 440 dataset. Since the dataset is spatially resolved, we were able to make this comparison across 441 442 regions of the nephron. We observed that our candidate protein set had stronger discriminatory power (i.e. significantly lower correlation; Fisher test, p=4.04e-11) than background in distal 443 convoluted tubule epithelial cells and in surrounding structures, but not in leukocytes or in 444 globally aggregated data (Figure 4). 445

This result gave us confidence that the 144-candidate set we report represents signatures of specific organ injury, and suggests that proteomic signals in distal convoluted tubule may be particularly representative of the extent to which injury impacts future functionality.

449 **DISCUSSION**

This study presents the first large unbiased human kidney tissue proteomics dataset for deceased donor kidneys. We examined the relationship between posttransplant kidney function with pretransplant kidney proteomes by analyzing 185 deceased donor kidneys with complete donor and recipient associated metadata. Although our study was not aiming to report a single biomarker, our large cohort, our unique machine learning approach, and finally alignment of proteomic data with a large spatial single cell transcriptomics dataset on healthy and diseased kidney substantiates our key findings. We describe an integration of kidney proteome with

clinical metadata and show that modelling age modulation of proteomic signals provides 457 enhanced resolution of donor kidney quality stratification and highlights biological mechanisms. 458 Our analysis reveals the importance of integrating across both subclinical and clinical 459 data. Exploring our data using iterative PRE feature selection, a substantial number of proteins 460 were revealed to be relevant, but only one clinical variable, donor age. Donor age is a key 461 contributor in clinical decisions and is a strongly weighted term in extant kidney allocation 462 scoring systems^{8,33}, but in the case of all reported candidate proteins, prediction models retained 463 a protein:donor age interaction term. This second-order effect has not (to our knowledge) been 464 explored in transplantation, and may be important to fully understanding molecular predictors. 465 A clinical variable notable by its omission from our association findings was donor 466 type³⁴. It is possible that outcome-predictive information 'carried' by donor type is also derivable 467 from the proteome (proteomic data were able to partially distinguish samples based on type even 468 when considering only variance across linear combinations of proteins; Figure S4). Without 469 disputing donor type-specific mechanisms of kidney damage³⁵, our data are consistent with the 470 idea that location and type of damage may be a greater contributor towards recovery potential³⁶ 471 472 than mechanism of injury.

Kidney metabolism is altered as a result of biological stress occurring during donor management, in both DBDs and DCDs³⁷. Within our final list of 144 proteins associated with outcome there is a common theme of implication in immune response to kidney injury (including both chronic injury, and acute injury) as a result of metabolic disruption, particularly responses associated with ischemia. We highlighted three proteins from our set of 144 outcome-associated candidates as a sanity check; all three are examples of known chronic damage indicators that we find here to have a donor organ pre-transplant predictive association.

480 Vitronectin (VTN) is a primary component of the extracellular matrix involved in cell 481 adhesion, enhancing the activity of plasminogen activator inhibitor-1 and inhibition of the 482 terminal complement pathway³⁸, and is a potential fibrotic biomarker³⁹.

Apolipoprotein E (APOE) stands out as having previously reported genetic allele age-483 related associations with disease and organ dysfunction including risk of Alzheimer's Disease⁴⁰ 484 (with the strongest effect manifesting around age 65^{41}), macular dysfunction, atherosclerosis and 485 pulmonary scarring^{42,43}, and evidence for shared allele risk across diseases⁴⁴. In kidneys, APOE 486 plays an important role in lipid metabolism to regulate the growth and survival of mesangial cells 487 and preserve organ function⁴⁵; it is a marker for outcome in transplant recipients^{46–48}, and there is 488 evidence for APOE genotype association with kidney dysfunction risk⁴⁹⁻⁵¹, possibly manifested 489 by lipidomic differences between allelic profiles⁵². We have previously reported small (not 490 statistically significant) increases in APOE due to ischemic reperfusion injuries⁵³ possibly 491 explained by a role in senescence mediation 54 . There is existing evidence for similar allele 492 dependent transplant outcome effects in another apolipoprotein (APOL1)⁵⁵, suggesting that both 493 APOE genotype and the broader apolipoprotein allelic profile may play an important role in 494 posttransplant graft function. 495

Cystatin C (CST3) is particularly noteworthy as, measured in serum, it is a known and
effective general biomarker for kidney function and has predictive power for outcomes in
transplant recipients⁵⁶⁻⁵⁸. Our evidence indicates a further association between CST3 levels in
donor kidney tissue and outcome; moreover, that this effect is age dependent, starting around age
40. Serum CST3 is relatively independent of age in children and young adults⁵⁹, but may also
show age association in later years⁶⁰.

502 A potential hurdle in contextualizing our findings in existing orthogonal transcriptomic data was that proteomes and transcriptomes are generally poorly correlated in terms of 503 abundance changes⁶¹. In order to avoid this problem, we considered how the pattern of injury 504 scenario-related differences changed between predictive and background signals within the same 505 transcriptomic dataset²⁹. The spatial component of this dataset further allowed us to show that 506 injury-specific signals within our 144-protein set localized most strongly to the distal convoluted 507 tubule (DCT) epithelium. Damage to DCT epithelial cells can be predictive of $outcome^{62}$; the 508 interplay of proximal and distal injury is complex⁶³, but previous work has suggested that DCT 509 epithelial cells can play an important protective and damage repair role across the nephron, 510 expressing survival and reparative factors in response to injury⁶⁴. Indications that aging is 511 associated with accumulation of senescent epithelial cells with a maladaptive stress response²⁹ 512 suggest a mechanism whereby aging related senescent cell accumulation could reduce the ability 513 of DCT epithelia cells to protect and promote recovery of injury sustained by the proximal 514 tubules. This would be consistent with our findings (immuno-metabolic and ischemia response 515 functional association, and spatially localized response) and the negative donor age correlation 516 with transplant outcome, and might explain recent successes with senescence inhibitors in 517 treating CKD⁶⁵, suggesting that routes to stimulate or enhance the DCT regenerative effect could 518 be avenues for organ preservation. 519

520 Our list of outcome-associated candidates cannot be exhaustive. Practicalities of sample 521 acquisition limited sampling of a wide range of outcomes outside the 30-60 donor age range, 522 especially limited Upper Tertile outcome events in older donors. Organ allocation algorithms 523 impose a close link between donor and recipient age in the sample cohort, so while we interpret 524 these age-moderated effects in terms of organ resilience in older donors, it could also represent a

525 greater ability to repair a given level of damage in younger recipients. Further, we consider only 526 chronological donor age, rather than a more nuanced representation of the epigenomic biological 527 clock ⁶⁶, which may to account for some variation observed with respect to both donors and 528 recipients.

It is immediately clear from our results that the strength of the donor age factor is 529 enormous relative to any other protein or clinical effect; this age effect is liable to dominate any 530 prediction weighting and reduce the accuracy of estimated protein contribution. A much larger 531 cohort could mitigate this issue, especially if paired with variant sequencing to understand 532 genetic diversity. Advances in high-throughput proteomics techniques continue to increase 533 feasible cohort sizes⁶⁷ but fundamental limitations on organ acquisition remain. Archiving at 534 scale of clinical samples in bioresources such as the QUOD biobank to parallel advancements in 535 big data analysis and interpretation platforms is therefore necessary for future development of 536 granular evidence-based decision making. 537

538 However, given the limitations of our dataset, our protein models generalized well to samples unseen during model training (Figure S5), and showed promise for outcome-539 classification prediction (Figure S6) suggesting that, with a larger training cohort to address the 540 541 caveats acknowledged above, a substantial component of early posttransplant outcome may be predictable solely using subclinical measurements moderated by donor age. The biological 542 543 themes of the 144 proteins identified herein reinforce known immuno-metabolic mechanisms of 544 kidney injury but raise interesting possibilities for further work, especially with regard to donor genetic background, and also suggest that the possibility of donor age-moderated weighting 545 should be considered as a matter of course in future work. 546

547

548 SUPPLEMENTARY MATERIALS

549 Supplementary Table ST1: Clinical variable p-values for association with donor type and

- 550 outcome.
- 551 Supplementary Table ST2: Summary of results for all candidate proteins.
- 552 Note that coefficient values provided are for linearized eGFR12, i.e. they relate to
- eGFR12 quantile ranging from 0 to 1.
- 554 Supplementary Figure S1: Donor and recipient clinical and demographic data association with
- recipient 12-month eGFR rank.
- 556 Single-linkage hierarchical clustering of curated, imputed clinical variables by relative

association strength (taking distance as 1-association). The outcome variable (ranked

recipient eGFR at 12 months post-transplantation) is highlighted in red.

559 Supplementary Figure S2: Protein quantification quality.

A: Missingness comparison: Proteins are shown ranked by the number of missing values across all samples and the twenty standard pools, excluding one run which was removed

562 due to low signal. 2984 proteins had missing values in 50% or less runs.

B: Paired Kidney Comparison: Protein abundance values from paired kidneys (left/right)

from 3 individual donors were compared, as these are effectively biological replicates. x

- axes: value in left kidney. y axes: value in right kidney. Inset: Pearson's r correlation
- 566 coefficient.

567 Supplementary Figure S3: Scree plot of variance represented by the first ten principle

568 components in the proteomic data.

A reasonable number for the cluster parameter (k) supplied for k-means clustering (see
Figure S4) lay between 3 and 5 based on the 'elbow' method'; we selected k=4.

Supplementary Figure S4: Unbiased analysis of pretransplant kidney proteomes and clusterassociations.

573	A: Unbiased analysis of proteomic data by k-means clustering. Sample separation by
574	Principal Component Analysis. Top Left: Samples were assigned to four clusters by k-
575	means. Bottom & Right: There was a difference in the distribution of DBD and DCD
576	donors across clusters, with the DBD donors being more heavily concentrated in Cluster
577	2 ('+' symbol; orange shading), and DCD in Cluster 4 ('x' symbol; pink shading)
578	B: There were no associations between proteome clusters and most donor and recipient
579	factors, except for mildly significant differences in donor BMI and creatinine (selected
580	comparisons shown; left-right, top-bottom: donor type, recipient 12-month posttransplant
581	eGFR (outcome), donor eGFR, donor age, donor BMI, donor creatinine at retrieval).
582	Supplementary Figure S5: Performance of individual protein with age models on unseen data.
583	For each protein, the protein term plus age term and protein: age interaction term were
584	modelled against linearized 12-month posttransplant eGFR (eGFR12) using LASSO. For
585	proteins passing filtering, with eGFR root-mean-square error (RMSE) better than an age-
586	only model, we compared the RMSE achieved on the model training data against the
587	RMSE achieved on held-out test data. We observed that the models actually achieved
588	slightly better performance on the test data, reassuring us that no model was over-fit to
589	the training data (i.e. all models generalized well to unseen data).
590	Supplementary Figure S6: Performance of VTN, APOE and CST3 models on paired kidney data.
591	Six of the analyzed kidneys were paired (i.e. two came from each of three donors). These
592	data were not used for training or testing but reserved for QC of the proteomics (Figure
593	S2). Although our analysis was focused on identification of outcome-associated protein

594	signals rather than prediction of eGFR12 (due to cohort size limitations, we do not claim
595	to have a maximally biologically representative training set), we nevertheless used these
596	paired kidneys to assess the consistency of our modelling in predicting above/below
597	median outcomes in the three proteins we highlighted as particularly interesting. In all
598	three pair cases the outcomes in (different) recipients were similar within each pair, and
599	for all three proteins the model consistently predicted the correct above/below median
600	classification for all six kidneys.
601	

601

602 DATA AND MATERIALS AVAILABILITY

603 The mass spectrometry proteomics data have been deposited to the ProteomeXchange

604 Consortium via the PRIDE ⁶⁸ partner repository with the dataset identifier PXD033428.

605

606 DISCLOSURE AND FUNDING

607 This study was supported by NHS Blood and Transplant funding awarded to MK & RJP. SF was

⁶⁰⁸ supported by Kidney Research UK, grant reference KS_RP_002_20210111 awarded to MK.

609 PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to

610 BMK. Authors declare that they have no competing interests.

611 Author contributions:

- 612 Conceptualization: MK
- 613 Methodology: PDC, SF, RV, SD, RF, BMK, AS, ES, RJP, MK
- 614 Investigation: PDC, SF, RV, PJ, SD, IV, KT, AS
- 615 Visualization: PDC

Funding acquisition: BMK, RJP, MK

- 617 Project oversight: MK
- 618 Supervision: RF, AS, MK
- 619 Writing original draft: PDC, ES, MK
- 620 Writing review & editing: All authors
- 621

622 **REFERENCES**

- Callaghan CJ, Mumford L, Pankhurst L, Baker RJ, Bradley JA, Watson CJE. Early
 Outcomes of the New UK Deceased Donor Kidney Fast-Track Offering Scheme.
 Transplantation. 2017;101(12):2888-2897. doi:10.1097/TP.00000000001860
- Summers DM, Johnson RJ, Hudson AJ, et al. Standardized deceased donor kidney donation rates in the UK reveal marked regional variation and highlight the potential for increasing kidney donation: a prospective cohort study[†]. *Br J Anaesth*. 2014;113(1):83-90.
 doi:10.1093/bja/aet473
- Benic A, Glassock RJ, Rule AD. The Kidney in Normal Aging: A Comparison with Chronic Kidney Disease. *Clin J Am Soc Nephrol*. 2022;17(1):137-139. doi:10.2215/CJN.10580821
- 4. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J
 Am Soc Nephrol. 2007;18(10):2758-2765. doi:10.1681/ASN.2007040422
- 5. Ishani A, Xue JL, Himmelfarb J, et al. Acute Kidney Injury Increases Risk of ESRD among
 Elderly. *J Am Soc Nephrol.* 2009;20(1):223-228. doi:10.1681/ASN.2007080837
- 6. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor
 age and cold storage time on outcome in recipients of kidneys donated after circulatory death
 in the UK: a cohort study. *Lancet*. 2013;381(9868):727-734. doi:10.1016/S01406736(12)61685-7
- Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for
 deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-236.
 doi:10.1097/TP.0b013e3181ac620b
- 8. Watson CJE, Johnson RJ, Birch R, Collett D, Bradley JA. A Simplified Donor Risk Index
 for Predicting Outcome After Deceased Donor Kidney Transplantation. *Transplantation*.
 2012;93(3):314-318. doi:10.1097/TP.0b013e31823f14d4
- Neuberger J, Callaghan C. Organ utilization the next hurdle in transplantation? *Transpl Int.*2020;33(12):1597-1609. doi:10.1111/tri.13744

Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor
 risk indices for deceased donor kidney transplant survival in the Australian and New Zealand
 population. *Nephrol Dial Transplant*. 2019;34(12):2127-2131. doi:10.1093/NDT/GFZ090

- 11. Yu K, Husain SA, King K, Stevens JS, Parikh CR, Mohan S. Kidney nonprocurement in
 deceased donors with acute kidney injury. *Clin Transplant*. Published online August 4,
 2022:e14788. doi:10.1111/ctr.14788
- Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated
 with kidney allograft failure. *Kidney Int*. 2019;95(1):199-209.
 doi:10.1016/j.kint.2018.08.047
- Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of
 Deceased Donor Acute Kidney Injury With Recipient Graft Survival. *JAMA Network Open*.
 2020;3(1):e1918634. doi:10.1001/jamanetworkopen.2019.18634
- Mansour SG, Khoury N, Kodali R, et al. Clinically adjudicated deceased donor acute kidney
 injury and graft outcomes. *PLoS One*. 2022;17(3):e0264329.
 doi:10.1371/journal.pone.0264329
- 15. von Moos S, Akalin E, Mas V, Mueller TF. Assessment of Organ Quality in Kidney
 Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet.
 Front Immunol. 2020;11:833. doi:10.3389/fimmu.2020.00833
- 666 16. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated
 by data-independent acquisition: a new concept for consistent and accurate proteome
 analysis. *Mol Cell Proteomics*. 2012;11(6):O111.016717. doi:10.1074/mcp.O111.016717
- 17. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma
 proteomics. *Mol Syst Biol*. 2017;13(9):942. doi:10.15252/msb.20156297
- 18. Connor KL, O'Sullivan ED, Marson LP, Wigmore SJ, Harrison EM. The Future Role of
 Machine Learning in Clinical Transplantation. *Transplantation*. 2021;105(4):723-735.
 doi:10.1097/TP.00000000003424
- Raynaud M, Aubert O, Divard G, et al. Dynamic prediction of renal survival among deeply
 phenotyped kidney transplant recipients using artificial intelligence: an observational,
 international, multicohort study. *The Lancet Digital Health*. 2021;3(12):e795-e805.
 doi:10.1016/S2589-7500(21)00209-0
- 20. Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks
 and interference correction enable deep proteome coverage in high throughput. *Nat Methods*.
 2020;17(1):41-44. doi:10.1038/s41592-019-0638-x
- Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization
 applied to microarray data calibration and to the quantification of differential expression.
 Bioinformatics. 2002;18(Suppl 1):S96-S104. doi:10.1093/bioinformatics/18.suppl_1.S96
- 4 22. Hastie T, Tibshirani R, Narasimhan B, Chu G. *Impute: Imputation for Microarray Data.*;
 2021. http://www.bioconductor.org/packages/release/bioc/html/impute.html

- 23. Fokkema M. Fitting prediction rule ensembles with R package pre. J Stat Softw. 686 2020;92(1):1-30. doi:10.18637/jss.v092.i12 687
- 24. Milborrow. Derived from mda:mars by T. Hastie and R. Tibshirani. S. Earth: Multivariate 688 Adaptive Regression Splines.; 2011. http://CRAN.R-project.org/package=earth 689
- 690 25. Jawaid W. EnrichR: Provides an R Interface to "Enrichr."; 2021. https://cran.rproject.org/package=enrichR 691
- 26. Csárdi G, Nepusz T. The igraph software package for complex network research. 692 InterJournal. 2006; Complex Systems: 1695. 693
- 27. Pons P, Latapy M. Computing Communities in Large Networks Using Random Walks. 694 (Yolum P, Güngör T, Gürgen F, Özturan C, eds.). Springer; 2005. doi:10.1007/11569596_31 695
- 28. Trucios C. StatPerMeCo: Statistical Performance Measures to Evaluate Covariance Matrix 696 Estimates.; 2017. https://CRAN.R-project.org/package=StatPerMeCo 697
- 29. Lake BB, Menon R, Winfree S, et al. An atlas of healthy and injured cell states and niches in 698 the human kidney. Nature. 2023;619(7970):585-594. doi:10.1038/s41586-023-05769-3 699
- 30. Fisher RA. Statistical Methods for Research Workers. Oliver and Boyd; 1925. 700 701 https://openlibrary.org/books/OL17638383M.opds
- 31. Diedenhofen B, Musch J. cocor: A Comprehensive Solution for the Statistical Comparison 702 703 of Correlations. PLoS ONE. 2015;10(4):e0121945. doi:10.1371/journal.pone.0121945
- 704 32. Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models 705 via Coordinate Descent. J Stat Softw. 2010;33:1-22. doi:10.18637/jss.v033.i01
- 33. Li B, Cairns JA, Robb ML, et al. Predicting patient survival after deceased donor kidney 706 transplantation using flexible parametric modelling. BMC Nephrol. 2016;17(1):51. 707 doi:10.1186/s12882-016-0264-0 708
- 34. Gill J, Rose C, Lesage J, Joffres Y, Gill J, O'Connor K. Use and Outcomes of Kidneys from 709 Donation after Circulatory Death Donors in the United States. J Am Soc Nephrol. 710 2017;28(12):3647-3657. doi:10.1681/asn.2017030238 711
- 35. Vaughan RH, Kresse JC, Farmer LK, et al. Cytoskeletal protein degradation in brain death 712 713 donor kidneys associates with adverse post-transplant outcomes. Am J Transplant. Published 714 online December 8, 2021. doi:10.1111/ajt.16912
- 36. Kosmoliaptsis V, Salji M, Bardsley V, et al. Baseline donor chronic renal injury confers the 715 716 same transplant survival disadvantage for DCD and DBD kidneys. Am J Transplant. 2015;15(3):754-763. doi:10.1111/ajt.13009 717
- 37. Damman J, Bloks VW, Daha MR, et al. Hypoxia and Complement-and-Coagulation 718
- Pathways in the Deceased Organ Donor as the Major Target for Intervention to Improve 719 Renal Allograft Outcome. Transplantation. 2015;99(6):1293-1300.
- 720
- doi:10.1097/TP.0000000000000500 721

38. De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N.
Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin. *EMBO Rep.* 2016;17(7):982-998. doi:10.15252/embr.201541681

- 39. Carreras-Planella L, Cucchiari D, Cañas L, et al. Urinary vitronectin identifies patients with
 high levels of fibrosis in kidney grafts. *J Nephrol*. 2021;34(3):861-874. doi:10.1007/s40620020-00886-y
- 40. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk,
 mechanisms, and therapy. *Nat Rev Neurol*. 2013;9(2):106-118.
 doi:10.1038/nrneurol.2012.263
- 41. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E
 genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
 PLoS Med. 2020;17(8):e1003289. doi:10.1371/journal.pmed.1003289
- 42. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev Genomics Hum Genet*. 2000;1:507-537. doi:10.1146/annurev.genom.1.1.507

43. Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging Roles of
Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung
Disease. *Am J Respir Cell Mol Biol*. 2016;55(2):159-169. doi:10.1165/rcmb.2016-0060TR

44. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia
independent of cerebral small-vessel disease. *Neurology*. 2014;82(12):1051-1057.
doi:10.1212/WNL.0000000000251

45. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for Kidney
Apolipoprotein E: REGULATION OF MESANGIAL CELL PROLIFERATION AND
MATRIX EXPANSION. *J Biol Chem.* 2001;276(52):49142-49147.
doi:10.1074/JBC.M104879200

- 46. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal
 transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function. *Clin Transplant*. 2004;18(3):288-294. doi:10.1111/j.1399-0012.2004.00162.x
- 47. Hernández D, Salido E, Linares J, et al. Role of apolipoprotein E epsilon 4 allele on chronic
 allograft nephropathy after renal transplantation. *Transplant Proc.* 2004;36(10):2982-2984.
 doi:10.1016/j.transproceed.2004.10.038
- 48. Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal transplantation. *Transplant Proc.* 2007;39(7):2217-2218.
 doi:10.1016/j.transproceed.2007.06.011
- 49. Czaplińska M, Ćwiklińska A, Sakowicz-Burkiewicz M, et al. Apolipoprotein e gene
 polymorphism and renal function are associated with apolipoprotein e concentration in
 patients with chronic kidney disease. *Lipids Health Dis.* 2019;18(1):1-9.
- 758 doi:10.1186/s12944-019-1003-x

759 760	50.	Hsu CC, Kao WHL, Coresh J, et al. Apolipoprotein E and progression of chronic kidney disease. <i>J Am Med Assoc</i> . 2005;293(23):2892-2899. doi:10.1001/jama.293.23.2892
761 762 763	51.	Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. <i>Trends Cardiovasc Med</i> . 2002;12(2):67-70. doi:10.1016/S1050-1738(01)00148-7
764 765 766	52.	Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. <i>Sci Transl Med.</i> 2021;13(583):eaaz4564. doi:10.1126/scitranslmed.aaz4564
767 768 769	53.	Huang H, van Dullemen LFA, Akhtar MZ, et al. Proteo-metabolomics reveals compensation between ischemic and non-injured contralateral kidneys after reperfusion. <i>Sci Rep</i> . 2018;8(1):8539. doi:10.1038/s41598-018-26804-8
770 771	54.	Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence. <i>Nature Aging</i> . 2022;2(4):303-316. doi:10.1038/s43587-022-00186-z
772 773 774	55.	Julian BA, Gaston RS, Brown WM, et al. Effect of Replacing Race with Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index. <i>Am J Transplant</i> . 2017;17(6):1540. doi:10.1111/AJT.14113
775 776 777	56.	Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. <i>Am J Kidney Dis.</i> 2000;36(1):29-34. doi:10.1053/ajkd.2000.8237
778 779 780 781	57.	Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. <i>Nephron Physiol</i> . 2003;94(2):19-27. doi:10.1159/000071287
782 783 784	58.	Rodrigo E, Ruiz JC, Fernández-Fresnedo G, et al. Cystatin C and albuminuria as predictors of long-term allograft outcomes in kidney transplant recipients. <i>Clin Transplant</i> . 2013;27(2):E177-83. doi:10.1111/ctr.12082
785 786 787	59.	Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin Ca new marker of glomerular filtration rate in children independent of age and height. <i>Pediatrics</i> . 1998;101(5):875-881. doi:10.1542/peds.101.5.875
788 789 790	60.	Edinga-Melenge BE, Yakam AT, Nansseu JR, et al. Reference intervals for serum cystatin C and serum creatinine in an adult sub-Saharan African population. <i>BMC Clin Pathol</i> . 2019;19:4. doi:10.1186/s12907-019-0086-7
791 792 793	61.	Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. <i>BMC Bioinformatics</i> . 2012;13(16):S12. doi:10.1186/1471-2105-13-S16-S12
794 795 796	62.	Oberbauer R, Rohrmoser M, Regele H, Mühlbacher F, Mayer G. Apoptosis of tubular epithelial cells in donor kidney biopsies predicts early renal allograft function. <i>J Am Soc Nephrol</i> . 1999;10(9):2006-2013. doi:10.1681/ASN.V1092006

- 63. Heyman SN, Rosenberger C, Rosen S. Experimental ischemia-reperfusion: biases and
 myths-the proximal vs. distal hypoxic tubular injury debate revisited. *Kidney Int.* 2010;77(1):9-16. doi:10.1038/ki.2009.347
- 64. Gobe GC, Johnson DW. Distal tubular epithelial cells of the kidney: Potential support for
 proximal tubular cell survival after renal injury. *Int J Biochem Cell Biol*. 2007;39(9):15511561. doi:10.1016/j.biocel.2007.04.025
- 65. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin
 in Patients with Chronic Kidney Disease. *N Engl J Med.* 2023;388(2):117-127.
 doi:10.1056/NEJMoa2204233
- 66. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
 ageing. *Nat Rev Genet*. 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3
- 67. Meier F, Brunner AD, Frank M, et al. diaPASEF: parallel accumulation–serial fragmentation
 combined with data-independent acquisition. *Nat Methods*. 2020;17(12):1229-1236.
 doi:10.1038/s41592-020-00998-0
- 68. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and
 resources in 2019: improving support for quantification data. *Nucleic Acids Res.*2019;47(D1):D442-D450. doi:10.1093/nar/gky1106
- 814

815 ACKNOWLEDGMENTS

- 816 We thank the UK QUOD Consortium and NHS Blood and Transplant UK Registry for providing
- the samples and the associated clinical and demographic metadata. ; in particular we thank Sheba
- 818 Ziyenge, Lewis Simmonds and Dr Sarah Cross, Dr Sergei Maslau and Mr Tomas Surik for their
- support on the QUOD sample selection.
- 820 We thank members of the Discovery Proteomics Facility within the TDI Mass Spectrometry
- Laboratory for expert help with mass spectrometry analysis, and members of the Lindgren group
- at the BDI for informative discussions regarding statistical modelling.

823 **FIGURES AND TABLES**



824

825 Figure 1: Experimental design to discover donor kidney proteome associations with transplant outcome

826 We selected biopsies from QUOD biobank taken from one kidney from each donor pair. Donor kidney samples

827 were selected randomly from pairs where both recipients had similar outcomes. The biopsy samples were subjected

828 to proteomic analysis to yield a snapshot of the organ proteome at kidney retrieval. We analyzed donor 829

characteristics and clinical variables and protein abundances in a combined model against recipient eGFR at 12

830 months posttransplant (eGFR12; units given in ml/min/1.73 m²).

Donor Type		DBD			DCD	
12m Outcome Tertile <i>ml/min/1.73 m</i> ²	Lower eGFR<40	Intermediate 40≤eGFR<60	Upper <i>eGFR≥60</i>	Lower eGFR<40	Intermediate 40≤eGFR≤60	Upper <i>eGFR≥60</i>
n	31	31	38	31	28	26
Donor Age, y	56.84 ± 12.29	51.32 ± 12.24	39.05 ± 14.12	55.48 ± 9.34	53.57 ± 9.75	38.31 ± 12.28
Donor Sex						
Male	15	16	19	22	16	16
Wate	(48.4%)	(51.6%)	(50.0%)	(71.0%)	(57.1%)	(61.5%)
Female	16 (51.6%)	15 (48.4%)	19 (50.0%)	(29.0%)	12 (42.9%)	10 (38.5%)
Donor Ethnicity	(31.070)	(+0.+70)	(30.070)	(29.070)	(42.970)	(30.370)
Donor Ennieky	30	30	36	30	28	25
White	(96.8%)	(96.8%)	(94.7%)	(96.8%)	(100.0%)	(96.2%)
Other	1	1	2	1	0	1
	(3.2%)	(3.2%)	(5.3%)	(3.2%)	(0.0%)	(3.8%)
Donor Weight, kg	+ 1820	/0.01 + 18.07	81.38 + 17.72	80.58 + 14.95	82.45 + 17.20	/8.0/ + 13.96
	168.42	169.52	174.82	169.97	171.64	174.65
Donor Height, cm	± 9.37	± 7.67	± 11.16	± 7.98	± 9.73	± 8.98
Donor S-Cr terminal,	86.54	82.57	90.19	73.37	70.31	59.60
_µmol/l	± 40.81	± 49.65	± 67.36	± 19.03	± 39.02	± 22.39
Donor CIT, h	15.80 + 3.88	14.20 + 4.60	13.42	13.65 + 5.20	11.72 + 3.55	12.80 + 4.49
Donor COD	± 5.00	± 4.00	± 4.07	± 5.20	± 5.55	± 1.12
_	1	3	3	4	3	4
Trauma	(3.2%)	(9.7%)	(7.9%)	(12.9%)	(10.7%)	(15.4%)
Other	30	28	35	27	25	22
	(96.8%)	(90.3%)	(92.1%)	(87.1%)	(89.3%)	(84.6%)
Donor UKKDRI	1.41 + 0.52	1.10 + 0.36	0.85 + 0.36	1.31 + 0.37	1.21 + 0.40	0.73
	53.03	52.10	39.71	51.90	50.93	44.92
Recipient Age, y	± 12.21	± 14.61	± 16.03	± 9.85	±11.04	± 12.87
Recipient Sex						
Female	15	8	12	11	9	5
1 emaie	(48.4%)	(25.8%)	(31.6%)	(35.5%)	(32.1%)	(19.2%)
Male	16 (51.6%)	23 (74, 2%)	26 (68,4%)	20	19 (67.9%)	21
Paginiant Ethnigity	(31.070)	(74.270)	(08.4%)	(04.570)	(07.9%)	(80.870)
Recipient Etimetry	24	21	20	22	23	20
White	(77.4%)	(67.7%)	(76.3%)	(71.0%)	(82.1%)	(76.9%)
Other	7	10	9	9	5	6
Other	(22.6%)	(32.3%)	(23.7%)	(29.0%)	(17.9%)	(23.1%)
Recipient Posttransplant K	idney Function (mean eGFR, ml/mi	in/1.73 m ²)			
3 months	29.71	50.32	78.54	31.72	46.50	77.88
	± 12.06	± 17.28	± 25.97	± 12.24	± 10.34	± 18.57
12 months	± 11.98	± 6.10	± 35.84	± 12.01	± 6.29	± 15.91
HLA Mismatch Groups						
O.M. (1	3	4	9	1	1	0
0 Mismatches	(10.0%)	(11.4%)	(25.7%)	(2.9%)	(4.2%)	(0.0%)
0 DR and 0/1 B	7	13	10	10	6	8
0 DP and 2 P	(23.3%)	(37.1%)	(28.6%)	(28.6%)	(25.0%)	(30.8%)
or 1 DR and $0/1$ R	(56.7%)	(40.0%)	(37.1%)	(60.0%)	(58.3%)	(53.8%)
1 DR and 2 B	3	4	3	3	3	4
or 2 DR	(10.0%)	(11.4%)	(8.6%)	(8.6%)	(12.5%)	(15.4%)

831 Table 1: Donor and recipient clinical and demographic variables

- 832 Donor kidney associated metadata. Samples are subdivided by donor type and by final assigned outcome tertile.
- Numerical variables are given \pm standard deviation. Categorial variables are given alongside percentage of total
- 834 cohort



В

Α



- Figure 2: Proteins predicting transplant outcome show immuno-metabolic functional associations, predict
 low eGFR outcomes and are consistent with Western Blot assay results.
- A: Shared Reactome pathway membership network analysis of filtered features. Nodes are colored by assigned
- 839 cluster, and the clusters are annotated according to the top three most enriched pathways within each cluster.
- 840 B: Western blots comparing younger (age \leq 49; mean age 34) and older (age \geq 58; mean age 64) donors between
- 841 Upper Tertile (UT; eGFR12 \geq 60) and Lower Tertile (LT; eGFR12 < 40) outcomes. As above, Left-Right: VTN,
- 842 APOE, CST3. Top row: representative western blots (n=5 per group) from comparison of younger donors. Middle
- row: representative western blots (n=5 per group) from comparison of older donors. Bottom row: result values for
- all quantified samples relative to the UT mean. UT values in green, LT values in blue. Error bars indicate ± 1
- standard deviation; the central wider bar indicates mean. Significance stars indicate t-test comparison p-values (***: p < 0.001, *: p < 0.05).
- p < 0.001, 2.5 p < 0.003).
- 847 All eGFR12 units given in ml/min/1.73 m^2

Cluster Label	Top 3 Shared Pathways
Immune Regulation & Complement Activation	Immune System
	Innate Immune System
	Regulation of Complement Cascade
Protein Metabolism and Regulation	Metabolism of Proteins
	Post-translational Protein Modification
	Post-translational Protein Phosphorylation
Metabolism	Metabolism
	Metabolism of Amino Acids and Derivatives
	Retinoid Metabolism and Transport
Cell Cycle	Cyclin E Associated Events During G1/S Transition
	Cyclin A:Cdk2-associated Events at S Phase Entry
	PCP/CE Pathway

848 **Table 2: Major Shared Pathway Network Clusters**

- 849 Proteins in Figure 2A were clustered by pathway membership, forming 4 major clusters (those with more than a
- 850 single member). We assigned summary labels to each cluster based on the top 3 pathways with shared membership in each cluster.
- 851



852

Figure 3: Modelled associations between proteins and kidney transplant outcome change with donor age

Our modelling found that the effect of candidate protein levels on outcome changed with age.

A: We quantile-normalized protein levels to a consistent scale and predicted outcome (12-month posttransplant

eGFR) across a representative donor age range. Using this prediction matrix to compare the interaction with age

between protein models, we found 3 major clusters (Left-Right; blue, pink and green dendrogram branches and

corresponding plot background color) representing increasing levels of age modulation. Moving Left-Right across

each plot, the eGFR12 (color scale, see key on right) contours across protein quantile (y axis) change as donor age

860 (x axis) increases.

B: Illustrative protein quantile-GFR12 plots are shown for each three proteins in each cluster. Traces are shown for

donor ages between 20 and 80 as labelled on the right end of each trace.



Lower AKI:CKD Correlation in Selected Genes vs Background; -log10(p-value)

863 Figure 4: Independent scRNA-seq Data Indicate Spatial Localization of the Outcome-Associated Signature

We reasoned that proteins/genes which predict outcome should associate with specific facets of organ injury rather than general inflammatory and stress response, and therefore would be expected to have a *lower* expression

correlation between acute and chronic damage scenarios than non-predictive other proteins/genes. We explored this

in a spatially resolved public transcriptomic dataset and found that the degree of correlation was significantly lower

for the set of 144 candidate predictors identified by our modelling approach, but that the signal appears to be

spatially localized, primarily to distal convoluted tubule epithelial cells and the epithelia of neighboring tubules

870 (indicated by red highlighting in right hand diagram).